Comparative Pharmacology
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus ORAMORPH SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus ORAMORPH SR.
DOLOPHINE HYDROCHLORIDE vs ORAMORPH SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with additional NMDA receptor antagonism and serotonin/norepinephrine reuptake inhibition. It also binds to delta and kappa opioid receptors, producing analgesic and antitussive effects.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
Initial: 2.5-10 mg orally every 8-12 hours, titrating to effect. Maintenance: 5-20 mg orally every 8-12 hours. For severe chronic pain, dosing interval may be extended to every 12-24 hours due to long half-life. Not recommended for acute pain or as PRN analgesia.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
None Documented
None Documented
Terminal elimination half-life: 15 to 60 hours (average 24-36 hours). Clinical context: Prolonged half-life due to extensive tissue binding and redistribution; accumulates with repeated dosing, requiring careful titration to avoid toxicity.
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Primarily renal elimination of unchanged drug (approximately 50-60%) and metabolites (including the inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). Fecal excretion accounts for about 10-20%. Biliary excretion contributes minimally (<5%) to overall elimination.
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic